MARK2 and congenital muscular dystrophy: Considering the importance of the serine/threonine kinase mTOR in metabolism regulation (Bodine et al., 2001; Fingar and Blenis, 2004; Giguère, 2018) and the well-described effects of sustained activation of the mTORC1 signaling pathway to promote skeletal muscle atrophy and loss in different pathological processes (Castets et al., 2013; Chiarini et al., 2019; Tang et al., 2014, 2019), we next investigated whether the increased myofiber diameter observed after treatment with vemurafenib was associated with the modulation of the mTORC1 signaling pathway in our animal model of LAMA2-CMD.